Oral Zonisamide Therapy
Phase 3Small molecule
Oral Zonisamide Therapy is one of 31 small molecule programs targeting Seizure. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Seizure
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Vimpat
UCBApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Epidiolex
Jazz PharmaceuticalsApproved
Tegretol
NovartisApproved
Trileptal
NovartisApproved
Fycompa
CCatalyst Biosciences
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Topamax
WWim Janssens
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Seizure1 trial
A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures
Recruiting·—·Phase 4·NCT06967012·30 enrolled
Chemoradiotherapy1 trial
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Recruiting·—·Phase 2·NCT07205536·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oral Zonisamide Therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details